Basilea Pharmaceutica Past Earnings Performance
Past criteria checks 0/6
Basilea Pharmaceutica has been growing earnings at an average annual rate of 55.8%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 4.7% per year.
Key information
55.8%
Earnings growth rate
55.5%
EPS growth rate
Biotechs Industry Growth | 18.9% |
Revenue growth rate | 4.7% |
Return on equity | -3.9% |
Net Margin | -0.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Revenue & Expenses Breakdown
How Basilea Pharmaceutica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 149 | -1 | 31 | 0 |
31 Mar 24 | 153 | 5 | 31 | 0 |
31 Dec 23 | 158 | 10 | 31 | 0 |
30 Sep 23 | 166 | 33 | 30 | 0 |
30 Jun 23 | 175 | 56 | 29 | 0 |
31 Mar 23 | 161 | 34 | 29 | 0 |
31 Dec 22 | 148 | 12 | 29 | 0 |
30 Sep 22 | 150 | 6 | 29 | 0 |
30 Jun 22 | 152 | 1 | 29 | 0 |
31 Mar 22 | 150 | -3 | 28 | 0 |
31 Dec 21 | 148 | -7 | 28 | 0 |
30 Sep 21 | 130 | -26 | 28 | 0 |
30 Jun 21 | 112 | -45 | 27 | 0 |
31 Mar 21 | 120 | -30 | 28 | 0 |
31 Dec 20 | 128 | -15 | 28 | 0 |
30 Sep 20 | 134 | -6 | 27 | 0 |
30 Jun 20 | 141 | 3 | 27 | 0 |
31 Mar 20 | 137 | -10 | 28 | 0 |
31 Dec 19 | 134 | -22 | 29 | 0 |
30 Sep 19 | 135 | -23 | 29 | 0 |
30 Jun 19 | 136 | -24 | 30 | 0 |
31 Mar 19 | 134 | -28 | 30 | 0 |
31 Dec 18 | 133 | -31 | 30 | 0 |
30 Sep 18 | 124 | -26 | 32 | 0 |
30 Jun 18 | 115 | -21 | 33 | 0 |
31 Mar 18 | 108 | -20 | 42 | 0 |
31 Dec 17 | 102 | -19 | 52 | 0 |
30 Sep 17 | 92 | -32 | 57 | 0 |
30 Jun 17 | 82 | -44 | 62 | 0 |
31 Mar 17 | 74 | -48 | 59 | 0 |
31 Dec 16 | 66 | -51 | 56 | 0 |
30 Sep 16 | 62 | -55 | 57 | 0 |
30 Jun 16 | 58 | -59 | 57 | 0 |
31 Mar 16 | 55 | -61 | 56 | 0 |
31 Dec 15 | 53 | -62 | 54 | 0 |
30 Sep 15 | 50 | -57 | 48 | 0 |
30 Jun 15 | 47 | -52 | 42 | 0 |
31 Mar 15 | 45 | -47 | 36 | 0 |
31 Dec 14 | 42 | -42 | 30 | 0 |
30 Sep 14 | 42 | -38 | 26 | 0 |
30 Jun 14 | 41 | -35 | 22 | 0 |
31 Mar 14 | 41 | -34 | 22 | 0 |
31 Dec 13 | 41 | -33 | 21 | 0 |
30 Sep 13 | 44 | -34 | 23 | 0 |
Quality Earnings: BSLN is currently unprofitable.
Growing Profit Margin: BSLN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BSLN is unprofitable, but has reduced losses over the past 5 years at a rate of 55.8% per year.
Accelerating Growth: Unable to compare BSLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BSLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.08%).
Return on Equity
High ROE: BSLN has a negative Return on Equity (-3.88%), as it is currently unprofitable.